BioLife Solutions (NASDAQ:BLFS) reported quarterly sales of $44.26 million which beat the analyst consensus estimate of $43.28 million by 2.26 percent. This is a 18.64 percent increase over sales of $37.30 million the same period last year.
HC Wainwright & Co. Reiterates Buy on Context Therapeutics, Maintains $4 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $4 price target.
